Abbott, Enanta ink HCV development pact

Abbott and Enanta Pharmaceuticals announced today that the companies have signed a worldwide deal to develop and commercialize hepatitis C virus NS3 and NS3/4A protease inhibitors. Enanta has discovered several HCV protease inhibitors that have demonstrated efficacy and pharmacokinetic profiles in pre-clinical studies. Upon closing, Enanta will receive an up-front payment of $57 million, which includes a cash payment and an equity investment. It also stands to receive up to $250 million in milestone payments.

- see the release on the pact

Related Article:
Abbott to buy Kos for $3.7B. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.